Christopher Barbieri
Christopher Barbieri
Associate Professor of Urology, Weill Cornell Medicine
Verified email at
Cited by
Cited by
The molecular taxonomy of primary prostate cancer
A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ...
Cell 163 (4), 1011-1025, 2015
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
CE Barbieri, SC Baca, MS Lawrence, F Demichelis, M Blattner, ...
Nature genetics 44 (6), 685-689, 2012
Punctuated evolution of prostate cancer genomes
SC Baca, D Prandi, MS Lawrence, JM Mosquera, A Romanel, Y Drier, ...
Cell 153 (3), 666-677, 2013
The long tail of oncogenic drivers in prostate cancer
J Armenia, SAM Wankowicz, D Liu, J Gao, R Kundra, E Reznik, ...
Nature genetics 50 (5), 645-651, 2018
Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis
CE Barbieri, LJ Tang, KA Brown, JA Pietenpol
Cancer research 66 (15), 7589-7597, 2006
The mutational landscape of prostate cancer
CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig, H Grönberg, ...
European urology 64 (4), 567-576, 2013
Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
X Dai, W Gan, X Li, S Wang, W Zhang, L Huang, S Liu, Q Zhong, J Guo, ...
Nature medicine 23 (9), 1063-1071, 2017
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover
C Geng, B He, L Xu, CE Barbieri, VK Eedunuri, SA Chew, M Zimmermann, ...
Proceedings of the National Academy of Sciences 110 (17), 6997-7002, 2013
DNA repair in prostate cancer: biology and clinical implications
J Mateo, G Boysen, CE Barbieri, HE Bryant, E Castro, PS Nelson, ...
European urology 71 (3), 417-425, 2017
SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling
M Blattner, D Liu, BD Robinson, D Huang, A Poliakov, D Gao, S Nataraj, ...
Cancer cell 31 (3), 436-451, 2017
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ...
Nature 571 (7765), 408-412, 2019
SPOP mutation leads to genomic instability in prostate cancer
G Boysen, CE Barbieri, D Prandi, M Blattner, SS Chae, A Dahija, ...
Elife 4, e09207, 2015
p63 and epithelial biology
CE Barbieri, JA Pietenpol
Experimental cell research 312 (6), 695-706, 2006
SPOP mutations in prostate cancer across demographically diverse patient cohorts
M Blattner, DJ Lee, C O'Reilly, K Park, TY MacDonald, F Khani, KR Turner, ...
Neoplasia 16 (1), 14-W10, 2014
Evidence for molecular differences in prostate cancer between African American and Caucasian men
F Khani, JM Mosquera, K Park, M Blattner, C O'Reilly, TY MacDonald, ...
Clinical Cancer Research 20 (18), 4925-4934, 2014
The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study
DM Golombos, A Ayangbesan, P O'Malley, P Lewicki, LM Barlow, ...
Urology 111, 122-128, 2018
N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
A Berger, NJ Brady, R Bareja, B Robinson, V Conteduca, MA Augello, ...
The Journal of clinical investigation 129 (9), 3924-3940, 2019
SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity
G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ...
Clinical cancer research 24 (22), 5585-5593, 2018
Association of procedure volume with radical cystectomy outcomes in a nationwide database
CE Barbieri, B Lee, MS Cookson, J Bingham, PE Clark, JA Smith, ...
The Journal of urology 178 (4), 1418-1422, 2007
TMPRSS2: ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia
K Park, JT Dalton, R Narayanan, CE Barbieri, ML Hancock, DG Bostwick, ...
Journal of clinical oncology 32 (3), 206, 2014
The system can't perform the operation now. Try again later.
Articles 1–20